Can helicobacter pylori infection reduce the risk of Multiple sclerosis? A systematic review and meta-analysis DOI Creative Commons
Fardin Nabizadeh, Nazanin Rafiei,

Seyedeh Maryam Vafaei

et al.

Neurology Letters, Journal Year: 2023, Volume and Issue: 2(2), P. 97 - 105

Published: July 1, 2023

Background: Several studies propose the protective effect of Helicobacter pylori (HP) in reducing risk Multiple sclerosis (MS) whereas others reported high HP seropositivity MS population. Hence, we aimed to perform a comprehensive systematic review and meta-analysis investigate association between infection.Methods: A literature search was performed using three databases June 2022. We selected observational that assessed HP.Results: total 14 articles with 2307 patients 2024 controls were included our meta-analysis. The pooled odds ratio (OR) estimates for 0.70 (CI 95%: 0.53-0.93) which indicates might reduce MS. OR developed countries 0.71(CI 0.57-0.87) while it 0.72 0.43-1.21) developing countries. Furthermore, prevalence 45% 35%-56%). overall estimated 32% 22%-41%). from 56% 43%-69%) higher than countries.Conclusion: In conclusion, this showed lower rate infection MS, suggesting may occurrence. However, further investigation large sample size adjusting other leading factors should be conducted confirm results.

Language: Английский

Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines DOI
Bassem Yamout, Mohammed Aljumah, Mohammad Ali Sahraian

et al.

Multiple Sclerosis and Related Disorders, Journal Year: 2024, Volume and Issue: 83, P. 105435 - 105435

Published: Jan. 7, 2024

Language: Английский

Citations

12
Endogenous retroviruses in multiple sclerosis: A network-based etiopathogenic model DOI Creative Commons
Stefano Censi,

Renato Mariani-Costantini,

Alberto Granzotto

et al.

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: 99, P. 102392 - 102392

Published: June 24, 2024

The present perspective article proposes an etiopathological model for multiple sclerosis pathogenesis and progression associated with the activation of human endogenous retroviruses. We reviewed preclinical, clinical, epidemiological, evolutionary evidence indicating how complex, multi-level interplay genetic traits environmental factors contributes to sclerosis. propose that in this process, retroviruses transactivation acts as a critical node disease development. also discuss rationale combined anti-retroviral therapy disease-modifying therapeutic strategy. Finally, we immuno-pathogenic process triggered by retrovirus can be extended aging aging-related neurodegeneration. In regard, envisioned act epigenetic noise, favoring proliferation disorganized cellular subpopulations accelerating system-specific "aging". Since inflammation are two sides same coin (plastic dis-adaptation external stimuli degree freedom), conditions may epiphenomenal products increased epigenomic entropy. Inflammation accelerates organ-specific aging, disrupting communication throughout systems body producing symptoms. Overlapping neurological symptoms syndromes emerge from activity shared molecular networks respond retroviruses' reactivation.

Language: Английский

Citations

4
Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study DOI Creative Commons
Paolo A. Muraro, Antonio Zito,

Alessio Signori

et al.

Annals of Neurology, Journal Year: 2025, Volume and Issue: unknown

Published: April 19, 2025

Objective To compare clinical and radiological outcomes among relapsing multiple sclerosis patients treated with autologous hematopoietic stem cell transplantation (AHSCT), alemtuzumab (ATZ), ocrelizumab (OCR). Methods From a London (UK) hospital‐based observational cohort, modeled data were obtained from 621 relapsing–remitting patients, who AHSCT (n = 103), ATZ 204), OCR 314), followed up for 43, 32 median months, respectively. The annualized relapse rate, new magnetic resonance imaging (MRI) lesions, disability progression on Expanded Disability Status Scale assessed. Results showed superior efficacy compared OCR. After 5‐year follow up, the mean rate (0.026 vs 0.087; p < 0.001), risk of relapses (HR 0.29, 95% CI 0.13–0.63; 0.002), MRI activity 0.33, 0.15–0.72; 0.006) significantly lower in versus group. Compared OCR, after 3‐year follow‐up (0.028 0.073; 0.02) trend to reduced 0.45, 0.18–1.14; 0.09), but similar low rates (6%) 0.86, 0.28–2.67; 0.80). In addition, there was AHSCT, both 1.19, 0.71–2.00; 0.50) 1.08, 0.57–2.04; 0.82) groups. Interpretation by greater prevention suppressed more profoundly than ATZ, similarly albeit shorter up. accumulating Studies larger sample sizes longer may enable confirmation these findings or detection any additional differential effects. ANN NEUROL 2025

Language: Английский

Citations

0
Current and Emerging Treatment Options in Pediatric Onset Multiple Sclerosis DOI Open Access
Artemis Mavridi,

Maria Eleni Bompou,

Aine Redmond

et al.

Sclerosis, Journal Year: 2024, Volume and Issue: 2(2), P. 88 - 107

Published: April 1, 2024

Pediatric onset multiple sclerosis (POMS), characterized by the of before age 18, is gaining increased recognition. Approximately 5 percent MS cases manifest with less than 1 occurring 10. Despite its rarity, pediatric exhibits distinct characteristics, an association between younger at and a comparatively slower disease progression. this progression, individuals POMS historically reach disability milestones earlier ages those adult-onset sclerosis. While various immunomodulatory agents demonstrate significant benefits in treatment, such as reduced relapse rates accumulation brain lesions on magnetic resonance imaging (MRI), majority disease-modifying therapies (DMTs) commonly used adult lack evaluation through clinical trials. Current evidence predominantly derived from observational studies. This comprehensive review aims to consolidate existing knowledge mechanisms action, efficacy, safety profiles, recommended dosages available DMTs specifically context MS. Furthermore, outlines recent advancements explores potential medications still developmental stages, providing thorough overview current landscape future prospects for treating POMS.

Language: Английский

Citations

3
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder — recommendations from ECTRIMS and the EBMT DOI Creative Commons
Paolo A. Muraro, Alice Mariottini, Raffaella Greco

et al.

Nature Reviews Neurology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 15, 2025

Language: Английский

Citations

0
Diagnostic performance of artificial intelligence in multiple sclerosis: a systematic review and meta-analysis DOI
Fardin Nabizadeh,

Elham Ramezannezhad,

Amirhosein Kargar

et al.

Neurological Sciences, Journal Year: 2022, Volume and Issue: 44(2), P. 499 - 517

Published: Oct. 27, 2022

Language: Английский

Citations

12
“A second birthday”? Experiences of persons with multiple sclerosis treated with autologous hematopoietic stem cell transplantation—a qualitative interview study DOI Creative Commons

Timo Volz,

Anna Sippel,

Felix Fischbach

et al.

Frontiers in Neurology, Journal Year: 2024, Volume and Issue: 15

Published: May 1, 2024

Autologous hematopoietic stem cell transplantation (aHSCT) is a promising treatment option for persons with multiple sclerosis (pwMS). Patients undergoing aHSCT face unique challenges in all aspects of life. In this study, we explored the lived experiences pwMS aHSCT. Semi-structured interviews 12 treated were conducted using maximum variation sampling strategy. Interviews transcribed verbatim and analyzed thematically inductive deductive categories. Three major themes identified: (1) preparing aHSCT, (2) experiencing procedure, (3) post-treatment time. A difficult decision-making process, organizational effort, funding difficulties characterized preparation transplantation. AHSCT was seen as life-changing event accompanied by both psychological physical stress, an associated feeling regaining control. The had lasting positive effect on lives interviewed pwMS. However, early time successes failures alike. Particularly independently organized medical aftercare perceived challenging. Retrospective revaluation has led most to wish earlier information provision about during their history. clear impact patients' psycho-social health, influencing perception life its quality. Assessing attending unmet needs patients before, during, after may positively influence experience

Language: Английский

Citations

2
Exploring the therapeutic potential of autologous hematopoietic stem cell transplantation in progressive multiple sclerosis—a systematic review DOI Creative Commons
Bente Braun,

Felix Fischbach,

Lena Kristina Pfeffer

et al.

European Journal of Neurology, Journal Year: 2024, Volume and Issue: 31(12)

Published: Aug. 5, 2024

Abstract Background and Purpose The aim was to determine the value of autologous haematopoietic stem cell transplantation (aHSCT) as a therapeutic intervention for progressive multiple sclerosis (PMS) based on systematic review current literature. Methods All studies from databases PubMed Google Scholar published in English before February 2024 which provided individual data PMS patients were systematically reviewed. PICO defined population (P), primary MS secondary patients; (I), treatment with aHSCT; comparison (C), none, disease‐modifying therapy treated/relapsing–remitting cohorts if available; outcome (O), transplant‐related mortality, progression‐free survival (PFS) no evidence disease activity. Results A total 15 met criteria including 665 (74 MS, 591 MS) 801 relapsing–remitting controls. PFS available 647 patients. showed more severe disability at baseline than average mortality 10 1.9%, deaths 528 ranged 0% 78% groups 5 years after initiation, demonstrating high variability. No activity scores 75%. Conclusion Based data, aHSCT does not halt progression people PMS. However, there appears be improved selected Due heterogeneity comprehensive clinical trials assessing efficacy across different patient are urgently needed reduce variability improve stratification.

Language: Английский

Citations

2
Current knowledge on multiple sclerosis pathophysiology, disability progression assessment and treatment options, and the role of autologous hematopoietic stem cell transplantation DOI
Georgios Gakis, Ioannis Angelopoulos,

Ioannis Panagoulias

et al.

Autoimmunity Reviews, Journal Year: 2023, Volume and Issue: 23(2), P. 103480 - 103480

Published: Nov. 25, 2023

Language: Английский

Citations

5
The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus DOI Creative Commons
de Sèze, Laurent Suchet,

Claude Mékiès

et al.

Neurology and Therapy, Journal Year: 2022, Volume and Issue: 12(2), P. 351 - 369

Published: Dec. 24, 2022

The treatment strategy in relapsing multiple sclerosis (RMS) is a complex decision requiring individualization of sequences to maximize clinical outcomes. Current local and international guidelines do not provide specific recommendation on the use immune reconstitution therapy (IRT) as alternative continuous immunosuppression management RMS. objective program was consensus-based expert opinion optimal IRT A Delphi method performed from May 2022 July 2022. Nineteen assertions were developed by scientific committee sent 14 French experts MS alongside published literature. Two consecutive reproducible anonymous votes conducted. Consensus recommendations achieved when more than 75% respondents agreed or disagreed with assertions. After second round, consensus amongst 16 out 19 propositions: 13 had 100% consensus, 3 above without consensus. Expert-agreed provided topics related benefit early immunological perspectives, profiles patients who may most (e.g. family planning, patient preference lifestyle requirements). These consensuses up-to-date relevant guidance practice. current reflects status knowledge should be updated timely manner further data become available.

Language: Английский

Citations

8